Prevent contract orientation & kick-off meeting contract#: 75N91019D00015 PP: 1/25/2019 to 2/24/2019
Ended Awarded
- Contract number
- 75N91019F00129
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,863
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Contract value 100% obligated
- $4,863.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
Sri International has been awarded a delivery order against the PREVENT Preclinical Drug Development Program (PREVENT) multiple award contract vehicle to provide orientation and kick-off meeting services for the PREVENT contract. This $4,863 cost-plus-fixed-fee order was issued by the National Cancer Institute, a component of the Department of Health and Human Services, and will be performed in West Menlo Park, California with a period of performance from January 25, 2019 through February 24, 2019 and a completion date of January 24, 2024. No set-aside provision was specified. Sri International will serve as the prime contractor to deliver the requested products and services under this order issued through the PREVENT program, which focuses on preclinical efficacy and intermediate endpoint biomarkers in drug development.
Quick answers
Who was awarded contract 75N91019F00129?
75N91019F00129 was awarded to Sri International by National Cancer Institute (National Institutes of Health) on January 24, 2019.
How much is contract 75N91019F00129 worth?
The government has obligated $4,863 on 75N91019F00129.
Is contract 75N91019F00129 an order under another contract?
Yes. 75N91019F00129 is a delivery order under 75N91019D00014, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019F00129 competed?
The extent of competition for 75N91019F00129 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award